Mode
Text Size
Log in / Sign up
Phase 3 N=46 Randomized Single-blind Treatment

Cytokine Removal in Cardiopulmonary Bypass Patients

Elective Cardiac Surgical Interventions

Enrolled (actual)
46
Serious AEs
0.0%
Results posted
Jan 2017
Primary outcome: Primary: IL-6 — 0; 0; 0; 0 pg/ml

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
CytoSorb (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Medical University of Vienna
Primary completion
May 2015

Outcome Measures

OutcomeResultp-value
PRIMARY
IL-6
0; 0; 0; 0; 62.9; 63.6

Summary

Cardiopulmonary bypass (CPB) surgery initiates a systemic inflammatory response induced by extrinsic (e.g. anesthesia, contact activation within the extracorporeal circuit, endotoxemia) and intrinsic (e.g. tissue damage, endothelial cell activation, ischemia-reperfusion injury of myocardium) factors. Monocytes are important players in systemic inflammation and the main producers of pro- and antiinflammatory cytokines. Monocytes activated by the extracorporeal circuit lead to a dysregulation of inflammatory homeostasis, increased levels of proinflammatory plasma mediators such as TNF-a, IL-1β, IL-6 and IL-18 are joined by antiinflammatory cytokines such as IL-10. This strong inflammatory response induces post surgical monocyte immunosuppression which is indicated by an impaired production of ex vivo LPS induced TNF-a production. Also malfunction of the peripheral circulation with increased lactate levels, pronounced fluid accumulation, increased need of vasopressors and cerebral dysfunction are observed. All of these factors may delay weaning from the ventilator, recovery of organ functions and discharge from ICU. Thus measures to decrease the inflammatory process have the potential to improve the perioperative course. Use of cytokine adsorbing circuit during CBP has an effect on circulation cytokine levels for the first 36 hours after surgery and induces a decreased inflammatory response for up to 3 days post surgery.

Eligibility Criteria

Inclusion Criteria

  • elective cardiac surgical intervention with an expected CBP duration >120 minutes

Exclusion Criteria

  • Emergency procedures
  • Heart transplantation
  • Elective left ventricular assist device (LVAD) implantation
  • Pulmonary thromendarterectomy
  • Declined informed consent
  • Serum creatinine > 2mg/dl
  • Body mass index 2mg/dl
  • History of Stroke
  • Bilirubin >2mg/dl
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01879176). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search